Kalaris Therapeutics (KLRS) Stock: Buy, Sell, or Hold?
KLRS - Kalaris Therapeutics, Inc. Common Stock
$3.90
-0.04 (-1.02%)
âŧ
5d:
-3.23%
30d:
-6.92%
90d:
-12.16%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When KLRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KLRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KLRS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KLRS is currently trading at $3.90, which is considered fair relative to its 30-day fair value range of $3.78 to $4.20.
Technical Outlook: Technically, KLRS is in a strong downtrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KLRS scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.71 (+379.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KLRS is in a strong downtrend. The price is currently testing key support at $3.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KLRS scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.71 (+379.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.78 -
$4.20
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 379.9% below Wall St target ($18.71)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.78 -
$4.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$4.31
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.35
Wall Street Target
$18.71
(+379.9%)
Share & Embed Analysis
Last updated: September 06, 2026 11:12 PM ET
Data refreshes hourly during market hours. Next update: 12:12 AM
Data refreshes hourly during market hours. Next update: 12:12 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KLRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Brett R Hagen
SELL
1915 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 59 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 46 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 40 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
